Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07059650 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 16 to 13v3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2025 to Aug 19, 2025 · Site details revised at 16 of 16 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Sep 2025 to Aug 19, 2025
    • Site details revised at 16 of 16 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.
Trial Details
NCT Number NCT07059650
Lead Sponsor Dizal Pharmaceuticals
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov